Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
50% Price Cut for Opdivo OK’ed with Estimated Sales of 151.6-Plus Billion Yen
The Central Social Insurance Medical Council, a health ministry reimbursement policy panel better known as Chuikyo, on November 16 agreed to ax the NHI prices of Opdivo (nivolumab) by 50% in February next year as an emergency step to curtail…
To read the full story
Related Article
- Ono Looks for New Growth through Opdivo Despite NHI Price Cut: President
February 16, 2017
- MHLW to Announce Opdivo’s New Prices on Nov. 24
November 24, 2016
- Chuikyo Floats Reimbursement Claims Based on “Amount Used” in Lieu of “Vial Units”
November 17, 2016
- Doctor, Industry Reps Get in Spat over Indication Additions: Chuikyo
November 17, 2016
- Opdivo’s NHI Price-Based Sales Put at Over 151 Billion Yen; 50% Cut Likely to Take Effect Feb. 1
November 15, 2016
- MHLW Plans 50% Price Cut for Opdivo
November 10, 2016
REGULATORY
- 4 Drug Makers Seek Govt Aid to Upgrade Aging Plants: LDP Hearing
August 24, 2026
- 679 Safety Reports Logged for Regenerative Medical Products in 2H FY2025
August 21, 2026
- Japan Panel to Discuss Approval of 6 NMEs, Leqembi SC on Aug. 26
August 20, 2026
- DPP Lawmaker Calls for Inflation Relief in 2027 Off-Year Drug Price Revision
August 19, 2026
- CEA Review Group Wraps Up Technical Debate, Urges More Company Access
August 19, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…